Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September:

• 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 2:25 p.m. ET at the Westin Copley Place in Boston.
• 17th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET at the Grand Hyatt New York.

A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with IBS with diarrhea.

Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005655/en/

Investor and Media Relations
Meredith Kaya, 617-374-5082
Vice President, Investor Relations and Corporate Communications
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

You May Also Be Interested In

• MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
• Bloom Energy Hits the Road with ESPN College Football Campus Tour to Bring the Power Conversation to Communities Nationwide
• EA SPORTS™ NHL® 27 Now Available Worldwide With 32 Authentic Arena Atmospheres and True-to-Life Team Playbooks